Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma

Human Pathology

Volumn 39, Issue 2, 2008, Pages 217-223

  Naka, Takahiko ^a   Kuester, Doerthe ^a   Boltze, Carsten ^a   Schulz, Torss Oliver ^a   Samii, Amir ^b   Herold, Christian ^b   Ostertag, Helmut ^b   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b NORDSTADT HOSPITAL   (Germany)

Author keywords

Chordoma; Matrix metalloproteinase; Plasminogen activator; Prognosis; Proteinase

Indexed keywords

CATHEPSIN B; CELL MARKER; CYTOKERATIN; CYTOKERATIN 5.2; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; UROKINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INFILTRATION; CELL DIFFERENTIATION; CHORDOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; GERMANY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MOLECULAR WEIGHT; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SKULL BASE TUMOR;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CATHEPSIN B; CHILD; CHORDOMA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; SKULL BASE NEOPLASMS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 38149141517     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.06.005     Document Type: Article

References (26)

1. Foukas A.F., Deshmukh N.S., Grimer R.J., Mangham D.C., Mangos E.G., and Taylor S. Stage-IIB osteosarcomas around the knee: a study of MMP-9 in surviving tumour cells. J Bone Joint Surg [Br] 84 (2002) 706-711
2. Uchibori M., Nishida Y., Nagasaka T., Yamada Y., Nakanishi K., and Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28 (2006) 33-42
3. Haeckel C., Czerniak B., Ayala A.G., Radig K., and Roessner A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer 79 (1997) 53-58
4. Haeckel C., Krueger S., Grote H.J., et al. Overexpression of cathepsin B and urokinase plasminogen activator is associated with increased risk of recurrence and metastasis in patients with chondrosarcoma. Cancer 89 (2000) 995-1003
5. Kawashima A., Okada Y., Nakanishi I., Ueda Y., Iwata K., and Roessner A. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. Gen Diagn Pathol 142 (1996) 129-137
6. Holton J., Steel T., Luxsuwong M., Crockard H., and Revesz T. Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. Neuropathol Appl Neurobiol 26 (2000) 497-503
7. O'Connell J.X., Renard L.G., Liebsch N.J., Efird J.T., Munzerider J.E., and Rosenberg A. Base of skull chordoma: a correlative study of histologic and clinical features of 62 cases. Cancer 74 (1994) 2261-2267
8. Volpe R., and Mazabraud A. A clinicopathologic review of 25 cases of chordoma: a pleomorphic and metastasizing neoplasm. Am J Surg Pathol 7 (1983) 161-170
9. Bergh P., Kindblom L., Gunterberg B., Remotti F., Ryd W., and Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 88 (2000) 2122-2134
10. Kumaki F., Matsui K., Kawai T., et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 159 (2001) 2125-2135
11. Sier C.F.M., Kubben F.J.G.M., Ganesh S., et al. Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74 (1996) 413-417
12. Herszenyi L., Plebani M., Carraro P., et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 86 (1999) 1135-1142
13. Murray G.I., Duncan M.E., O'Neil P., McKay J.A., Melvin W.T., and Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. J Pathol 185 (1998) 256-261
14. Kawano N., Osawa H., Ito T., et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 28 (1997) 613-622
15. Young T.N., Rodriguez G.C., Rinehart A.R., Bast R.C., Pizzo S.V., and Stack M.S. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 62 (1996) 89-99
16. Kallakury B.V.S., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., and Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
17. Schmalfeldt B., Prechtel D., Haerting K., et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 7 (2001) 2396-2404
18. Katayama A., Bandoh N., Kishibe K., et al. Expression of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 10 (2004) 634-640
19. Oezen O., Krebs B., Hemmerlein B., Pekun A., Kretzschmar H., and Herms J. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. Clin Cancer Res 10 (2004) 4746-4753
20. Ueda Y., Imai K., Tsuchiya H., et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol 148 (1996) 611-622
21. Ahrens D., Koch A.E., Popo R.M., Stein-Picarella M., and Niedbala M.J. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39 (1996) 1576-1577
22. Naka T., Boltze C., Kuester D., et al. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, B. cathepsin, and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol 122 (2004) 926-930
23. Smith J., Ludwig R.L., and Marcove R.C. Sacrococcygeal chordoma: a clinicopathological study of 60 patients. Skeletal Radiol 16 (1987) 37-44
24. Haeckel C., Krueger S., Kuester D., et al. Expression of cathepsin K in chordoma. Hum Pathol 31 (2000) 834-840
25. Naka T., Boltze C., Kuester D., et al. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical study of 122 lesions. Am J Clin Pathol 124 (2005) 288-294
26. Naka T., Iwamoto Y., Shinohara N., Chuman H., Fukui M., and Tsuneyoshi M. Cytokeratin subtyping in chordomas and fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol 10 (1997) 545-551